Endogenously bound calmodulin is essential for the function of the inositol 1,4,5-trisphosphate receptor

被引:28
|
作者
Kasri, NN
Török, K
Galione, A
Garnham, C
Callewaert, G
Missiaen, L
Parys, JB
De Smedt, H
机构
[1] Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium
[2] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England
[3] St Georges Univ London, Dept Basic Med Sci, London SW17 0RE, England
关键词
D O I
10.1074/jbc.M510971200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Calmodulin ( CaM) is a ubiquitous Ca2+ sensor protein that plays an important role in regulating a large number of Ca2+ channels, including the inositol 1,4,5- trisphosphate receptor ( IP3R). Despite many efforts, the exact mechanism by which CaM regulates the IP3R still remains elusive. Here we show, using unidirectional Ca-45(2+) flux experiments on permeabilized L15 fibroblasts and COS- 1 cells, that endogenously bound CaM is essential for the proper activation of the IP3R. Removing endogenously bound CaM by titration with a high affinity ( pM) CaM- binding peptide derived from smooth muscle myosin light- chain kinase ( MLCK peptide) strongly inhibited IP3- induced Ca2+ release. This inhibition was concentration- and time- dependent. Removing endogenously bound CaM affected the maximum release capacity but not its sensitivity to IP3. A mutant peptide with a strongly reduced affinity for CaM did not affect inhibited IP3- induced Ca2+ release. Furthermore, the inhibition by the MLCK peptide was fully reversible. Re- adding exogenous CaM, but not CaM1234, reactivated the IP3R. These data suggest that, by using a specific CaM- binding peptide, we removed endogenously bound CaM from a high affinity CaM- binding site on the IP3R, and this resulted in a complete loss of the IP3R activity. Our data support a new model whereby CaM is constitutively associated with the IP3R and functions as an essential subunit for proper functioning of the IP3R.
引用
收藏
页码:8332 / 8338
页数:7
相关论文
共 50 条
  • [31] Mapping the site of inositol 1,4,5-trisphosphate receptor ubiquitination
    Sliter, Danielle
    Kirkpatrick, Donald
    Alzayady, Kamil
    Gygi, Stephen
    FASEB JOURNAL, 2008, 22
  • [32] THE CALMODULIN-BINDING DOMAIN IN THE MOUSE TYPE-1 INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR
    YAMADA, M
    MIYAWAKI, A
    SAITO, K
    NAKAJIMA, T
    YAMAMOTOHINO, M
    RYO, Y
    FURUICHI, T
    MIKOSHIBA, K
    BIOCHEMICAL JOURNAL, 1995, 308 : 83 - 88
  • [33] PUTATIVE RECEPTOR FOR INOSITOL 1,4,5-TRISPHOSPHATE SIMILAR TO RYANODINE RECEPTOR
    MIGNERY, GA
    SUDHOF, TC
    TAKEI, K
    DECAMILLI, P
    NATURE, 1989, 342 (6246) : 192 - 195
  • [34] INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR EXPRESSION IN CARDIAC MYOCYTES
    MOSCHELLA, MC
    MARKS, AR
    JOURNAL OF CELL BIOLOGY, 1993, 120 (05): : 1137 - 1146
  • [35] IS DECAVANADATE A SPECIFIC INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR ANTAGONIST
    STRUPISH, J
    WOJCIKIEWICZ, RJH
    CHALLISS, RAJ
    SAFRANY, ST
    WILLCOCKS, AL
    POTTER, BVL
    NAHORSKI, SR
    BIOCHEMICAL JOURNAL, 1991, 277 : 294 - 294
  • [36] Inositol 1,4,5-trisphosphate receptor phosphorylation in breast cancer
    Soghoian, D
    Jayaraman, V
    Silane, M
    Berenstein, A
    Jayaraman, T
    TUMOR BIOLOGY, 2005, 26 (04) : 207 - 212
  • [37] EXPRESSION OF AN INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IN CARDIAC MYOCYTES
    MOSCHELLA, MC
    MARKS, AR
    CIRCULATION, 1992, 86 (04) : 345 - 345
  • [38] Another look at regulation of the inositol 1,4,5-trisphosphate receptor
    Ehrlich, BE
    Striggow, F
    Kaftan, EJ
    JOURNAL OF PHYSIOLOGY-LONDON, 1997, 499P : S2 - S2
  • [39] Modulation of inositol 1,4,5-trisphosphate binding to the various inositol 1,4,5-trisphosphate receptor isoforms by thimerosal and cyclic ADP-ribose
    Vanlingen, S
    Sipma, H
    De Smet, P
    Callewaert, G
    Missiaen, L
    De Smedt, H
    Parys, JB
    BIOCHEMICAL PHARMACOLOGY, 2001, 61 (07) : 803 - 809
  • [40] Selective determinants of inositol 1,4,5-trisphosphate and adenophostin A interactions with type 1 inositol 1,4,5-trisphosphate receptors
    Rossi, Ana M.
    Sureshan, Kana M.
    Riley, Andrew M.
    Potter, Barry V. L.
    Taylor, Colin W.
    BRITISH JOURNAL OF PHARMACOLOGY, 2010, 161 (05) : 1070 - 1085